IL-17A Promotes the Migration, Invasion and the EMT Process of Lung Cancer Accompanied by NLRP3 Activation

Figure 2

IL-17A did not affect lung cancer cells proliferation. (a) CCK-8 assay showed that IL-17A administration (50 ng/ml, 100 ng/ml) did not affect A549 cells proliferation at 24 h or 48 h compared to control group. (b) Representative real-time traces of cell index indicated that IL-17A (50 ng/ml, 100 ng/ml) treatment have a similar proliferation curve in A549 cells. (c) CCK-8 assay showed that IL-17A administration (50 ng/ml, 100 ng/ml) did not affect H1299 cells proliferation at 24 h or 48 h. (d) Representative real-time traces of cell index in each group indicated that cell proliferation does not appear to be affected by IL-17A (50 ng/ml, 100 ng/ml) treatment in H1299 cells. One-way ANOVA. Error bars, mean ± SD. ns, non-signifcant; SD, standard deviation.

(a)

(b)

(c)

(d)